501. Implementation and Outcomes of a Program to Coordinate and Administer Monoclonal Antibody Therapy to Long-Term Care Facility Residents with COVID-19

BACKGROUND: Long-term care facility (LTCF) residents are at increased risk of severe COVID-19, with CMS data indicating > 20% mortality. BLAZE-1 trial noted lower hospitalization rates in high-risk patients receiving monoclonal antibody (mAb) vs placebo (4.2% vs 14.6%) for mild to moderate infect...

Descripción completa

Detalles Bibliográficos
Autores principales: Watkins, Andrew B, Brand, Lisa M, Schwedhelm, Michelle, Jensen, Heather L, Scott, Brandon, German, Dan K, Strand, Kyle P, Kamal-Ahmed, Ishrat, Lawler, James, Salman Ashraf, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644488/
http://dx.doi.org/10.1093/ofid/ofab466.700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644488/
http://dx.doi.org/10.1093/ofid/ofab466.700

Ejemplares similares